Nektar Therapeutics (NKTR)

Nektar Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	35.28	88.23	25.22	198.96	96.36
Short-Term Investments	268.34	416.75	708.74	862.94	1,228
Cash & Cash Equivalents	303.62	504.98	733.96	1,062	1,325
Cash Growth	-39.88%	-31.20%	-30.88%	-19.85%	-0.79%
Receivables	1.21	5.98	22.49	38.89	36.8
Inventory	16.1	19.2	15.8	15.29	12.67
Other Current Assets	9.78	15.81	23.33	21.93	47.22
Total Current Assets	330.7	545.97	795.58	1,138	1,422
Property, Plant & Equipment	36.86	85.89	177.54	186.14	199.84
Long-Term Investments	25.83	0	64.83	136.66	279.12
Goodwill and Intangibles	0	76.5	76.5	76.5	76.5
Other Long-Term Assets	4.64	2.25	2.74	1.46	0.34
Total Long-Term Assets	67.33	164.63	321.61	400.76	555.81
Total Assets	398.03	710.6	1,117	1,539	1,977
Accounts Payable	9.85	12.98	9.75	22.14	19.23
Deferred Revenue	0	0	0	0	8.07
Current Debt	19.26	18.67	17.44	13.92	265.41
Other Current Liabilities	22.16	36.56	58.01	79.73	61.18
Total Current Liabilities	51.27	68.2	85.2	115.78	353.89
Long-Term Debt	98.52	112.83	125.74	136.37	142.73
Other Long-Term Liabilities	117.26	162.93	226.75	209.32	75.34
Total Long-Term Liabilities	215.78	275.76	352.48	345.69	218.07
Total Liabilities	267.05	343.96	437.68	461.47	571.97
Total Debt	117.78	131.5	143.18	150.29	408.14
Debt Growth	-10.43%	-8.16%	-4.73%	-63.18%	65.27%
Retained Earnings	-3,477.25	-3,201.19	-2,833	-2,309.16	-1,864.72
Comprehensive Income	0.08	-6.91	-4.16	-2.3	-1.01
Shareholders' Equity	130.99	366.64	679.51	1,077	1,405
Net Cash / Debt	185.84	373.48	590.78	911.61	916.73
Net Cash / Debt Growth	-50.24%	-36.78%	-35.19%	-0.56%	-15.77%
Net Cash Per Share	0.98	2.00	3.22	5.10	5.24
Working Capital	279.43	477.76	710.38	1,022	1,068
Book Value Per Share	0.69	1.96	3.71	6.03	8.03

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).